Skip to main
SXTP
SXTP logo

SXTP Stock Forecast & Price Target

SXTP Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

60 Degrees Pharmaceuticals Inc has demonstrated impressive financial growth, with net product revenues increasing by 140% to $607.6k in FY24 and showing a 223% year-over-year rise in Q3 FY25. The continued growth in ARAKODA deliveries, up 14% from the previous year, highlights a strong demand for the product and indicates ongoing sales momentum. Additionally, the favorable safety profile of tafenoquine suggests potential for expanded clinical applications, offering further opportunities for revenue growth and diversification in the company's product lineup.

Bears say

60 Degrees Pharmaceuticals Inc faces significant challenges that contribute to a negative outlook on its stock. The firm reported a sequential decline in product revenues to $100,000 due to supply constraints, despite gaining some offset from Australian research grant revenue, indicating instability in core product performance. Furthermore, the reported gross loss of approximately $9,000, due to a one-time inventory write-off, in combination with low visibility on regulatory approvals and potential dilution from financing, raises substantial concerns about the company’s financial health and future profitability.

SXTP has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 60 Degrees Pharmaceuticals Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 60 Degrees Pharmaceuticals Inc (SXTP) Forecast

Analysts have given SXTP a Strong Buy based on their latest research and market trends.

According to 2 analysts, SXTP has a Strong Buy consensus rating as of Dec 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.40, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.40, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

60 Degrees Pharmaceuticals Inc (SXTP)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.